Antisense modulation of RNA processing as a therapeutic approach in cancer therapy

Lee Spraggon; Luca Cartegni

doi:10.1016/j.ddstr.2013.06.002

Antisense modulation of RNA processing as a therapeutic approach in cancer therapy

Lee Spraggon, Luca Cartegni

Ernest Mario School of Pharmacy, Chemical Biology

Research output: Contribution to journal › Review article › peer-review

10 Scopus citations

Abstract

Next-generation antisense technologies are re-emerging as viable and powerful approaches to the treatment of several genetic diseases. Similar strategies are also being applied to cancer therapy. Reprogramming of the expression of endogenous oncogenic products to replace them with functional antagonists, by interfering with alternative splicing (AS) or polyadenylation, provides a promising novel approach to address acquired drug resistance and previously undruggable targets.

Original language	English (US)
Pages (from-to)	e139-e148
Journal	Drug Discovery Today: Therapeutic Strategies
Volume	10
Issue number	3
DOIs	https://doi.org/10.1016/j.ddstr.2013.06.002
State	Published - 2013

All Science Journal Classification (ASJC) codes

Molecular Medicine
Pharmacology
Drug Discovery

Access to Document

10.1016/j.ddstr.2013.06.002

Cite this

@article{67a6a71a66114d17b069546f6a185e9b,

title = "Antisense modulation of RNA processing as a therapeutic approach in cancer therapy",

abstract = "Next-generation antisense technologies are re-emerging as viable and powerful approaches to the treatment of several genetic diseases. Similar strategies are also being applied to cancer therapy. Reprogramming of the expression of endogenous oncogenic products to replace them with functional antagonists, by interfering with alternative splicing (AS) or polyadenylation, provides a promising novel approach to address acquired drug resistance and previously undruggable targets.",

author = "Lee Spraggon and Luca Cartegni",

note = "Publisher Copyright: {\textcopyright} 2013 Elsevier Ltd.",

year = "2013",

doi = "10.1016/j.ddstr.2013.06.002",

language = "English (US)",

volume = "10",

pages = "e139--e148",

journal = "Drug Discovery Today: Therapeutic Strategies",

issn = "1740-6773",

publisher = "Elsevier Ltd",

number = "3",

}

TY - JOUR

T1 - Antisense modulation of RNA processing as a therapeutic approach in cancer therapy

AU - Spraggon, Lee

AU - Cartegni, Luca

PY - 2013

Y1 - 2013

N2 - Next-generation antisense technologies are re-emerging as viable and powerful approaches to the treatment of several genetic diseases. Similar strategies are also being applied to cancer therapy. Reprogramming of the expression of endogenous oncogenic products to replace them with functional antagonists, by interfering with alternative splicing (AS) or polyadenylation, provides a promising novel approach to address acquired drug resistance and previously undruggable targets.

AB - Next-generation antisense technologies are re-emerging as viable and powerful approaches to the treatment of several genetic diseases. Similar strategies are also being applied to cancer therapy. Reprogramming of the expression of endogenous oncogenic products to replace them with functional antagonists, by interfering with alternative splicing (AS) or polyadenylation, provides a promising novel approach to address acquired drug resistance and previously undruggable targets.

UR - http://www.scopus.com/inward/record.url?scp=84883252529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883252529&partnerID=8YFLogxK

U2 - 10.1016/j.ddstr.2013.06.002

DO - 10.1016/j.ddstr.2013.06.002

M3 - Review article

AN - SCOPUS:84883252529

SN - 1740-6773

VL - 10

SP - e139-e148

JO - Drug Discovery Today: Therapeutic Strategies

JF - Drug Discovery Today: Therapeutic Strategies

IS - 3

ER -

Antisense modulation of RNA processing as a therapeutic approach in cancer therapy

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this